Zydus Cadila Plans Indian Remdesivir Entry In July
Interferon Studies In Mexico, IND in US
Executive Summary
Zydus Cadila hopes to launch its version of Gilead’s remdesivir by end-July in India, even as earlier licensees Hetero Drugs and Cipla have just commercialized the antiviral. Plans for pegylated interferon alfa-2b to treat COVID-19 include a trial in Mexico and an IND in the US. Separately, desidustat is being considered for additional indications.
You may also be interested in...
Mylan Has Green Light On Remdesivir
Lauding a “significant milestone for Mylan, for the global public health community and, most importantly, for patients who are battling this pandemic,” Mylan has received approval in India for its remdesivir 100mg/vial product licensed from Gilead Sciences.
What's Next? Five Things To Look Out For In July
In the month ahead, Mylan and Upjohn will at last begin to make final preparations for their proposed combination while second-quarter results are expected from large cap companies including Novartis’ Sandoz, Amgen, Biogen and Pfizer.
Remdesivir Rivals Hit Indian Market
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.